Provided by Tiger Fintech (Singapore) Pte. Ltd.

Takeda Pharmaceutical Co Ltd

14.43
-0.3100-2.10%
Post-market: 14.430.00000.00%16:53 EDT
Volume:3.64M
Turnover:52.90M
Market Cap:45.57B
PE:64.28
High:14.72
Open:14.72
Low:14.41
Close:14.74
Loading ...

Press Release: Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Dow Jones
·
30 Jan

Takeda Pharmaceutical Says Hema-Quebec to Cover HyQvia for Immunodeficiency Treatment

MT Newswires Live
·
29 Jan

Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age

CNW Group
·
29 Jan

Takeda Pharmaceutical Expected to Post Lower Third-Quarter Net Profit -- Earnings Preview

Dow Jones
·
29 Jan

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Benzinga
·
28 Jan

Stocks to Watch: Graco, Brown & Brown, Neurocrine Biosciences

Dow Jones
·
28 Jan

Neurocrine Amends Collaboration with Takeda on Osavampator

MT Newswires Live
·
28 Jan

Neurocrine Amends Agreement With Takeda for Major Depressive Disorder Treatment

Dow Jones
·
28 Jan

Neurocrine announces amendment to collaboration with Takeda

TIPRANKS
·
28 Jan

Keros to Receive $200 Million From Takeda In Connection to Elritercept License Deal

MT Newswires Live
·
21 Jan

Takeda Recognized as a Top Employer in Canada for Third Consecutive Year

CNW Group
·
21 Jan

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

GlobeNewswire
·
21 Jan

Takeda Canada Says Health Canada Granted Market Authorization for Fruzaqla

MT Newswires Live
·
21 Jan

Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)

CNW Group
·
20 Jan